US-NJ, Exec Dir - Global Head, Portfolio Mgmt, Analytics and BD&L Finance 211936BR-MZ
Exec Dir - Global Head, Portfolio Mgmt, Analytics and BD&L Finance
East Hanover, NJ
Audit & Finance
The Executive Director will be responsible for Portfolio Management, Analytics & BD&L Finance. The Executive Director will be :
Shaping, implementing, govern broad and complex Global Oncology portfolio with integration of GSK assets and Targeted Therapies/Immuno-Therapies (more than 50 assets).
Providing recommendation on development/ commercial investment choices, integrating external trends/ internal factors with supportive quantitative and qualitative impact on Oncology business.
Navigating through the matrix to achieve cross BU senior stakeholder alignment.
Partnering with Global Head Strategy and BD&L to identify, evaluate and successfully close deals. As part of the portfolio responsibility benchmark external deals with internal programs. Deals include licensing, M&A (in co-ordination with Group M&A) and asset spin-off/ divestments.
Developing portfolio analytics and governance framework & process. Align and coordinate implementation with GDD portfolio management team.
Conducting and facilitate regular portfolio value analysis based on external and internal factors for Oncology Disease Strategy Committee decision making
Leading portfolio optimization projects and portfolio analysis in close cooperation with ECS, GDD, Global Finance, marketing and market access
Leading and facilitate twice yearly deep dive portfolio review at DSC in alignment with Global Head Marketing, Strategy and BD&L, NIBR, ECS, OGD and Finance
Monitoring external market trends, conduct regular comparisons with competitors portfolio
Understanding and follow external portfolio valuation done by investors and analysts
Aligning financial asset valuation analysis between internal and external assets considered for licensing
Leading and drives independent, high quality financial support to all BD&L transactions including Licensing, Acquisition, Divestments, Co-Promotion and other strategic business initiatives.
Making recommendations for financial structure and terms in order to maximize value to Novartis while minimizing risk
Leading alignment from key finance (FRA, Tax, Funds Flow) stakeholders and incorporate their feed-back in term sheet/contract in a timely manner.
Leading analysis of financial models underpinning deal terms; analyzes deal economics quickly to identify key value drivers and looks at key sensitivities.
Overseeing & drive the preparation of P&L s, discounted cash flow analyses and sensitivity analyses, CAR forms and fi-nancial slides for DRC
Be a trusted member of the Deal Team; has the ability to act as a trusted member of the Deal Team in face to face negotiations with external parties, including those which are particularly large or complex
Constructively challenge deal terms which do not meet internal targets or are perceived to be inappropriate in terms of risk to Novartis
Lead a team of 3 directors and guide them appropriately for the above activities
The Novartis Group of Companies are Equal Opportunity Employers and take pride in maintaining a diverse environment. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status.
Master's Degree or MBA required
Minimum of 10 years of experience in one or a combination of Finance, BD&L, Portfolio Management required
Financial analysis expertise
Knowledge of oncology business and international experience preferred
Direct People Management experience preferred
Proven leadership through influence in cross-cultural settings
* If a direct employer requests that you go to their web site and complete your application there in order to be
considered, please do so. Applications for all positions are subject to each employer's specific requirements.